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This study aimed to evaluate the orofacial antinociceptive effect of the Cymbopogon winterianus essential oil (LEO) complexed in
𝛽-cyclodextrin (LEO-CD) and to assess the possible involvement of the central nervous system (CNS). The LEO was extracted,
chromatographed, and complexed in 𝛽-cyclodextrin. The complex was characterized by differential scanning calorimetry (DSC)
and thermogravimetry derivative (TG/DTG). Male Swiss mice (2-3 months) were treated with LEO-CD (50–200mg/kg, p.o.),
vehicle (distilled water, p.o.), or standard drug (i.p.) and subjected to the orofacial nociception formalin-, capsaicin-, and glutamate-
induced. After the formalin test, the animals were perfused and the brains subjected to immunofluorescence for Fos. The rota-rod
test (7 rpm/min) was carried out. Geraniol (37.57%) was the main compound of LEO. DSC and TG/DTG proved the complexation.
The orofacial nociceptive behavior was significantly (𝑝 < 0.05) reduced.The number of Fos-positive cells was significantly changed
in the dorsal raphe nucleus (𝑝 < 0.01), locus coeruleus (𝑝 < 0.001), trigeminal nucleus (𝑝 < 0.05), and trigeminal thalamic tract
(𝑝 < 0.05). LEO-CD did not cause changes in motor coordination in the rota-rod test. Thus, our results suggested that LEO-CD
has an orofacial antinociceptive profile, probably mediated by the activation of the CNS without changing the motor coordination.
1. Introduction
Pain is defined by the International Association for the Study
of Pain (IASP) as an unpleasant sensory and emotional
experience associated with actual or potential tissue damage
or described in terms of such damage [1]. The orofacial pain,
which has a central origin, has emerged as a worldwide health
problem. It is estimated that over 22% of Americans, over 18
years, experience pain in the orofacial region.This prevalence
is repeated in countries such as England and Germany [2].
Various medicaments have been proposed in an attempt
to alleviate orofacial pain; however, many patients do not
respond adequately to this type of treatment, demonstrating
the need for further studies in order to obtain effective drugs
regarding this pathology [3].
Natural products, such as medicinal plants, have been a
source of new therapeutic proposals in an attempt to obtain
new drugs or precursors with a specific formulation [4].
Studies have demonstrated the effect of natural products
on several pathologies and symptoms. In this context are
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the terpenes and monoterpenes inserted for the pain treat-
ment [5–8].
The use of cyclodextrins (CDs), which are cyclic oligosac-
charides, has been described in oral pharmaceutical formu-
lations by means of the formation of inclusion complexes.
Several advantages for the drugs are established such as solu-
bility, dissolution rate, stability, bioavailability enhancement,
modification of the drug release site and/or time profile and
reduction or prevention of gastrointestinal side effects as well
as unpleasant smell or taste, or even the conversion of oil and
liquid drugs intomicrocrystalline or amorphous powders [9–
11]. According toTiwari et al. [12], about 30medicines contain
in their formulas the CDs available in the pharmaceutical
market, such as the tiaprofenic acid, nimesulide, omeprazole,
and cephalosporin normally used in the clinical setting
[13]. In order to solubilize nonpolar molecules, or complex
mixtures such as essential oils, the formation of inclusion
complexes with CDs has been extensively used [10, 14, 15].
Following this approach, our group has recently studied
the complexation of natural products, mainly terpenes or
essential oils with CDs, seeking to improve the chemical and
pharmacological properties of these compounds [15–18].
Cymbopogon winterianus Jowitt ex Bor is a tropical plant
with various pharmacological applications including its main
compounds (citronellal, citronellol, and geraniol), such as
cardiovascular [19], anti-inflammatory, antinociceptive [6,
20], and central nervous system (CNS) disorders [21, 22].
However, the analgesic effect of this oil on orofacial pain
models still has not been studied. The CNS areas activated
after C. winterianus leaf essential oil (LEO) administration
and its antinociceptive profile are little studied although it
continues to be used in folk medicine to treat pain and
inflammation, which indicates its high pharmacological and
biotechnological potential. Additionally, its short half-life
and poor solubility in water have limited the application in
medicine.
Hence, we aimed to evaluate the orofacial antinociceptive
profile as well as the CNS involvement of LEO complexed in
𝛽-cyclodextrin (LEO-CD) in rodents, being the first study in
the literature that reports the complexation of LEO in 𝛽-CD,
its assessment in CNS areas using protein Fos protein as tool,
and evaluation of its effect on orofacial pain animal models.
2. Materials and Methods
2.1. Chemicals. Chemicals are Alexa Fluor 488 (Life Tech-
nologies, Carlsbad, California, USA); c-fOS polyclonal anti-
body (Santa Cruz Biotechnology, Dallas, Texas, USA); cap-
saicin (Sigma, USA); formalin (UFS, Brazil); gelatin (UFS,
Brazil); glutamate (Sigma, USA); ketamine (Crista´lia, Brazil);
morphine (Merck, Brazil); solution of sodium chloride (UFS,
Brazil); Bovine Serum Albumin (BSA) (Santa Cruz, USA);
sucrose solution (UFS, Brazil); phosphate buffered saline
(UFS, Brazil); and xylazine (Crista´lia, Brazil).
2.2. Obtaining of the Essential Oil. The LEO was obtained by
collecting the leaves of the same plant (Arie Blank, ASE9389)
at the Federal University of Sergipe, Brazil, Station of
Research of the “Rural Campus of the UFS” (latitude 11∘00󸀠S
and longitude 37∘12󸀠W). The leaves with essential oil (LEO)
were obtained through hydrodistillation in a Clevenger appa-
ratus, in which the leaves of C. winterianus were deposited
and dried in an ovenwith circulation and renewal of air (MA-
037/18 model) at 40∘C to achieve complete dehydration.
2.3. Gas Chromatography (GC). GC analyses were performed
using the gas chromatography equipment coupled to a mass
spectrometer with flame ionization detector (GC-MS/FID)
(GC-2010 Plus, GCMS-QP2010 Ultra, Shimadzu Corpora-
tion, Kyoto, Japan) equipped with an autosampler AOC-20i
(Shimadzu). The separations were carried out using a Restek
Rtx-5MS fused silica capillary column (5% polysiloxane-
diphenyl-95%dimethyl) of 30m× 0.25mm internal diameter
(di) and 0.25mm in film thickness at a constant flow of
helium (99.999%) with a rate of 1.2mLmin−1. The oven
temperature program used was from 50∘C (isothermal for
1.5min) with an increase of 4∘C/min, up to 200∘C, and then
10∘C/min to 250∘C ending with 5min isotherm at 250∘C.
The FID andMS data were simultaneously acquired using
a system of separation detector. The split ratio was 4 : 1 flow
(MS : FID). A tube restrictor 0.62m × 0.15mmdi (capillary
column) was used to connect the splitter to the MS detector.
A tube restrictor 0.74m × 0.22mm i.d. was used to connect
the splitter to the FID. The injector temperature was 250∘C
and the ion source temperature was 200∘C. A mass spectrum
was generated at 70 eV with a scan speed of 0.3 sec scan
being detected in the range of 40–350. The FID fragment
temperature was adjusted to 250∘C and the supply of gas to
the FID was synthetic air, hydrogen, and helium flow rates
of 30, 300, and 30mL⋅min−1, respectively. The quantification
of each constituent was estimated by normalizing the peak
of the FID generated (%) area. The concentrations of the
compoundswere calculated from theGCpeak areas andwere
arranged in order of elution from the GC.
The identification of the components was performed
based on the comparison of the retention index described in
the literature [23]. In order to calculate the retention index
(RI), the Van Den Dool and Kratz [24] ratio equation for
a homologous series of n-alkanes (nC9–nC18) was used.
Three libraries, WILEY8, NIST107, and NIST21 equipment
which allow the comparison of the spectral data with those
contained in the libraries, using a similarity index of 80%,
were also used.
2.4. Preparation of the Inclusion Complex. The complex was
prepared according to the procedure described by Pinto et
al. [25], which consisted of the following steps: (1) physical
mixture (PM): LEO (taking into account the weight of the
major component LEO, geraniol, 154.24 g/mol) and 𝛽-CD
(1135 g/mol) were mixed (1 : 1 mole ratio) mechanically at
ambient conditions, (2) kneading (KN): the LEO and 𝛽-CD
weremixed (1 : 1 mole ratio) with then adding 2.0mL of water
and homogenizing the preparation in mortar and pestle, and
(3) coevaporation (CE): LEOand𝛽-CDweremixed (1 : 1mole
ratio) in 60mL of water under constant stirring (36 h) in
400 rpm until equilibrium. Hence, the samples were dried in
a glass desiccator and after that were removed and stored in
amber vials.
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2.5. Characterization of Complex. The samples were sub-
jected to differential and scanning calorimetry (DSC), ther-
mogravimetry derivative (TG/DTG). The DSC curves were
obtained onDSC-50 cell (Shimadzu) using aluminum sample
holder with 2mg of sample in an atmosphere of nitrogen
(50mL/min−1) and heating rate of 10∘C min−1 in the tem-
perature range from 25 to 500∘C. The DSC cell was checked
with indium (RM 156.6∘C, ΔHmel = 28.54 Jg-1) and zinc (PF
419.6∘C). The TG/DTG curves were obtained in thermobal-
ance model TGA 50 (Shimadzu) using a temperature range
of 25–900∘C in a platinum sample holder with ∼3mg of
sample under dynamic nitrogen atmosphere (50mL/min−1)
and heating rate of 10∘C/min−1. The thermobalance was
verified with CaC
2
O
4
⋅H
2
O.
2.6. Scanning ElectronMicroscopy (SEM). Thedried products
were mounted and visualized with a JEOL Model JSM-7410-
F scanning electron microscope, at an accelerated voltage of
1 kV.
2.7. Animals. Adult (3-month-old) male albino Swiss mice
(28–32 g) were randomly housed (𝑛 = 6/per group) in appro-
priate cages at 21±2∘Cwith a 12 hr light: dark cycle (light from
06:00 to 18:00), with free access to food (Purina, Brazil) and
tapwater. All experiments were carried out between 09:00 am
and 02:00 pm in a quiet room. Experimental protocols were
approved by the Animal Care and Use Committee at the
Federal University of Sergipe (CEPA/UFS number 42/12).
The ethical principles established by the Brazilian Society for
Laboratory Animal Science (SBCAL) and by the National
Institutes of Health (NIH) were respected. All tests were
carried out by the same blinded visual observer and all efforts
were made to minimize the number of animals used as well
as minimize any discomfort. Vehicle and experimental drug
were performed orally by gavage.
2.8. Formalin-, Capsaicin-, and Glutamate-Induced Orofacial
Nociception. These tests consisted of the subcutaneous injec-
tion of formalin (20 𝜇L; 2%) [26], capsaicin (20𝜇L, 2.5𝜇g), or
glutamate (40 𝜇L, 25 𝜇M) [27] on the right upper lip. Initially,
each animal was placed in a mirrored box (30 × 30 × 30 cm)
for 30min tominimize stress.Then, the injection of formalin,
capsaicin, or glutamatewas performed and, immediately after
that, the animals returned to the box for the observation
period, divided into 2 blocks of 0–5min and 15–30min,
1 block of 42min or 1 block of 15min for the formalin,
capsaicin, and glutamate tests, respectively. The nociceptive
intensity was determined by measuring the time (s) that the
animal spent face-rubbing in the injected area with its fore or
hind paws. In order to assess the effect of the test drug, mice
were pretreated with LEO-CD (50, 100, and 200mg/kg, p.o.),
distilled water (p.o.), or morphine (MOR, 5mg/kg, i.p.), 1 h
before the local injection of the agents.
2.9. Assessment of the Motor Activity. In order to evaluate
the possible nonspecificmuscle-relaxant or sedative effects of
LEO-CD in the doses used, mice were subjected to rota-rod
apparatus (AVS, Brazil) [28], adapted by Quintans-Ju´nior
et al. [27]. The animals were selected 24 h previously, elimi-
nating those mice which did not remain on the bar for two
consecutive periods of 180 s. Animals were treated with LEO-
CD (50, 100, and 200mg/kg, p.o.), vehicle (distilled water,
p.o.), or diazepam (DZP, 1.5mg/kg, i.p.) and observed at
times of 30, 60, 120, and 180min after treatment in a rotating
frequency of 7 rpm and for 180-second bar. The results are
expressed as the average time(s) the animals remained on the
rota-rod in each group.
2.10. Immunofluorescence for Fos. Based on studies con-
ducted by Barr [29], immediately after the formalin-induced
orofacial nociception test, the animals were perfused and had
their brains removed and cryoprotected for immunofluores-
cence processing to Fos protein as described by Brito et al.
[30].
Frozen serial transverse sections (20𝜇m) of all brains
were collected on gelatinized glass slides. The tissue sections
were stored at−80∘Cuntil use.The sectionswere washedwith
phosphate buffer (0.01M) saline isotonic (PBS) 5 times for
5min and incubated with 0.01M glycine in PBS for 10min.
Nonspecific protein binding was blocked by incubation of
the sections for 30min in a solution containing 2% BSA.
Then, the sections were incubated overnight with rabbit anti-
Fos as primary antibodies (k-25; 1 : 2000). Afterwards, the
sections were incubated for two hours with donkey anti-
rabbit Alexa Fluor 488 as secondary antibodies (1 : 2000).
The cover slip was mounted with glycerol solution. As an
immunofluorescence control for nonspecific labeling, sec-
tions were incubated without primary antibody. After each
stage, slides were washed with PBS 5 times for 5min.
2.11. Acquisition and Analyses of Images. Pictures from Fos-
positive areaswere acquired for each animalwith anOlympus
IX2-ICB (Tokyo, Japan). The brain regions were classified
according to Paxinos and Franklin Atlas [31]. Neurons were
counted by the free software Image J (National Institute of
Health) using a plug-in that uses the same level of label
intensity to select and count the Fos-positive cells [30].
2.12. Statistical Analysis. Results were expressed as mean ±
S.E.M. Differences between groups were analyzed using one-
way analysis of variance (ANOVA) followed by Tukey’s
test. In all cases, differences were considered significant if
𝑝 < 0.05. The statistical analyses were assessed using the
GraphPad Prism 5.0 software (GraphPad Prism Software Inc.,
San Diego, CA, USA).
3. Results
The qualitative analysis of the LEO sample through GC-
MS allowed observing the presence of 20 components. The
major constituents of the essential oil were geraniol (37.57%),
citronellal (27.09%), geranial (9.63%), citronellol (9.53%), and
neral (7.32%) (Table 1).
The DSC curve of LEO exhibited an endothermic event
at 146∘C followed by decomposition with loss of mass (Δ𝑚)
of 93.3%, while the DSC curve of 𝛽-CD showed three
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Table 1: Chromatographic profile of leaf essential oil of C. winterianus Jowitt ex Bor (LEO) by GC-MS.
Peak TR (min) Compounds (%)GC-MS
(%)
GC/FID IRR exp.
∗ IRR lit.∗∗
1 10.505 6-Methyl-5-hepten-2-one 0.22 0.22 988 981
2 12.060 Limonene 1.36 2.03 1031 1024
3 12.980 Bergamal 0.26 0.33 1056 1051
4 13.675 NI 0.31 0.30 1074 NI
5 14.705 Linalool 0.58 0.73 1102 1095
6 15.815 NI 0.17 0.24 1131 NI
7 16.520 Isopulegol 0.42 0.43 1150 1145
8 16.795 Citronellal 27.09 28.55 1157 1148
9 17.180 Z-Isocitral 0.31 0.22 1167 1160
10 17.875 E-Isocitral 0.31 0.34 1185 1177
11 18.710 n-Decanal 0.34 0.34 1208 1201
12 19.575 Citronellol 9.53 10.14 1231 1223
13 20.095 Neral 7.32 6.94 1246 1235
14 20.615 Geraniol 37.57 35.43 1260 1249
15 21.180 Geranial 9.63 8.99 1275 1264
16 24.010 Acetate of citronella 0.54 0.40 1355 1350
17 25.075 Acetate of geraniol 1.45 1.22 1386 1379
18 26.550 E-Caryophyllene 0.34 0.52 1430 1417
19 31.910 Caryophyllene oxide 0.28 0.41 1597 1582
20 39.635 NI 1.97 2.21 1844 NI
RT = retention time, GC-MS = gas chromatography coupled to mass spectrometry, GC/FID = gas chromatography with flame ionization detector, IRR exp.∗
= experimental retention index, IRR lit.∗∗ = retention index found in literature, and NI = not identified.
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Figure 1: Curve of mass loss (%) (a) and of the heat flow (b) versus temperature (∘C) of essential oil of C. winterianus Jowitt ex Bor (LEO)
and 𝛽-cyclodextrin (𝛽-CD) alone and in physical mixture (PM) process and coevaporation (CE).
endothermic events (27–120∘C: Δ𝑚 = 12.51%, 212–232∘C: Δ𝑚
= 277–345∘C:Δ𝑚= 72.88%), followed by an exothermic event
(Δ𝑚 = 10.76%). The coevaporation DSC curve made three
endothermic events followed by decomposition. In curves,
TG/DTG results are expressed in these four stages of mass
loss, in a similar manner to PM. However, in the temperature
range of 120–270∘C, the TG/DTG curve of CE showed amass
loss of 18.02%, while the PM had a percentage mass loss of
only 1.99%. The DSC curve of PM showed two endothermic
events (27–152∘C and 269–326∘C) (Figure 1). The TG/DTG
curve confirms this result showing four stages of mass loss
of MF (Table 2), which indicates the complexation of LEO in
𝛽-CD (LEO-CD).
SEM micrographs show the different magnifications of
the 𝛽-CD, physical mixture (PM), and slurry complex (SC).
By using the SEM, in Figure 2(a), one can see the different
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Table 2: Percentages of mass loss and steps of thermal decomposi-
tion of the LEO,𝛽-cyclodextrin (𝛽-CD), physical mixture (PM), and
LEO/𝛽-CD (CE) complex.
Mass loss %
1st stage 2nd stage 3rd stage 4th stage
LEO 93.94# — — —
𝛽-CD 12.51∗ — 72.88∗∗ 10.76∗∗∗
PM 21.06+ 1.99++ 67.22∗∗ 11.20∗∗∗
CE 13.39+ 18.02++ 54.48∗∗ 10.86∗∗∗
#Percentage of leaf essential oil of C. winterianus (LEO) evaporated to 291∘C.
∗Percentage of released water to 120∘C. +Loss related to the evaporation of
the LEO and release of water up to 120∘C mass. ++Loss attributed to the
release of LEO weight in the range 120–270∘C. ∗∗Thermal decomposition in
the range 270–365∘C. ∗∗∗Training elemental carbon due to charring in the
range 365–900∘C.
sizes of rectangular-shaped and small particles that adhered
to the surfaces of the crystals. Figure 2(b) shows an aspect
similar to Figure 2(a), which demonstrates the low capacity of
molecular inclusion. However, Figure 2(c) allows observing
the amorphous structure.The originalmorphology of the raw
materials disappeared and this property is attributed to the
formation of inclusion complexes.
Administration of LEO-CD produced a reduction in the
face-rubbing behavior induced by formalin (Figure 3). All the
doses of LEO-CD tested significantly (𝑝 < 0.05) reduced
nociceptive behavior in the first and in the secondphasewhen
compared with control (vehicle).
In the orofacial nociception induced by capsaicin, LEO-
CD, in all doses, significantly decreased (𝑝 < 0.01) the face-
rubbing time (nociceptive behavior) when compared with
the control group (Figure 4(a)). Similar effects were observed
in the glutamate-induced nociception test, where LEO-CD
reduced significantly (𝑝 < 0.001), at doses of 100 and
200mg/kg, the nociceptive behavior when compared with
the vehicle group (control) (Figure 4(b)).The reference drug,
morphine, significantly produced (𝑝 < 0.001) face-rubbing
time in both protocols.
In the rota-rod test, LEO-CD-treated mice, in all doses,
did not show any significant motor performance alteration
(data not shown). The CNS depressant drug, diazepam
(1.5mg/kg, i.p., standard drug), reduced the time of treated
animals on the rota-rod apparatus, as it might be expected.
Pretreatment with LEO-CD produced significant neu-
ronal activation (𝑝 < 0.05) by immunohistochemistry for c-
fos protein in the dorsal raphe (DR) nucleus, locus coeruleus
(LC), trigeminal nucleus (TN), and trigeminothalamic tract
(TTT) when compared to the control group (Figures 5 and
6).
4. Discussion
The genus Cymbopogon, belonging to the family Poaceae, is
rich in essential oil of aromatic character [21]. C. winterianus
Jowitt ex Bor, popularly known as “citronella grass,” is one
of the main Brazilian highlights and it is a medicinal plant
species widely distributed in northeastern Brazil [32]. Some
pharmacological properties attributed to LEO have been
described by our group, such as cardiovascular, analgesic, and
anti-inflammatory [19, 20, 33] properties. However, lowwater
solubility, short half-life, and low absorption by oral adminis-
trations have limited pharmacological uses of essential oils or
main compounds [10, 15].Thus, we assessed the effect of LEO
complexed in 𝛽-CD on orofacial nociception protocols and
its action on theCNS by immunofluorescence for Fos protein.
Our study demonstrated that LEO possesses a chromato-
graphic profile similar to that presented by Leite et al. [20, 33]
and deMenezes et al. [19], in which the major components of
LEO are geraniol, citronellal, geranial, citronellol, and neral.
According to Stotz and collaborators [34] that showed that
the geraniol, geranial, and neral act in vanilloid receptor 1,
indicating the possible inhibitory effect of these compounds
on the painful behavior. In addition, the effect of citronellol
[30] and citronellal [27] on orofacial pain models has also
been described with pharmacological mechanisms which
may be considered innovators to monoterpenes, such as
sodium channel blockers and involving the descending pain-
inhibitory mechanisms. Therefore, we proceeded with the
complexation of LEO with cyclodextrin and performed the
characterization of these inclusion complexes to the best of
our knowledge for the first time in literature.The endodermal
event observed on the DSC curve of LEO is typical of the
volatilization of oil, which can be seen by the curvesTG/DTG,
where the mass loss of the oil is observed.
The DSC curve of 𝛽-CD resulted in three endothermic
events. The first is referring to the release of water molecules
in their molecular structure, the second is a characteristic
crystalline phase transition where there is no mass change,
being a physical phenomenon, and the third is related to
the melting followed by decomposition of the material.
Thereafter, it began to decompose exothermically with the
formation of elemental carbon, which is the fourth stage of
mass loss.TheDSC curve of the PM showed two endothermic
events.The range of 27–152∘C comprises the sum of the phase
of water release from the 𝛽-CDmolecule and volatilization of
LEO, and the temperature range of 269–326∘C is an observed
process of degradation.
These results are a clear evidence of the formation of
inclusion complexes, since the oil encapsulated in 𝛽-CD, by
the CE method, can not volatilize at temperatures below
120∘C. As it needs a higher temperature for this process to
occur, it is possible to suggest the presence of oil in the
cavity of 𝛽-CD. However, in the PM, the volatilization of
LEO occurred in the first stage of mass loss, which has a
21.06% removal of water molecules as well as LEO possibly
adsorbed on the surface of 𝛽-CD [15, 35]. Thus, we obtained
a novel complex formed by LEO with 𝛽-CD. In addition,
the dose tested in our protocols is substantially smaller than
the smallest dose of LEO described in the literature by Leite
et al. [20], because we used the 1 : 1 molar ratio of majority
compound (geraniol: 154.24 g/mol) and 𝛽-CD (1135 g/mol),
so we are using nominally around 10% of the dose used by
Leite et al. [20]. Therefore, this complex seems to present
better analgesic effect using lower concentrations of active
ingredient, with these benefits being already described for
cyclodextrins [36, 37].
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Figure 2: SEM micrographs of cross sections of (a) 𝛽-CD, (b) physical mixture (PM), and (c) slurry complex (SC). 1000x and 2000x.
In addition, to evaluate the possible orofacial antinoci-
ceptive profile of LEO-CD, some protocols were carried out.
The first protocol was the formalin-induced nociception test.
This test is the most appropriate test for central review, being
divided into two phases [26]. The first phase refers to a direct
stimulation of nociceptors by the release of substance P (SP),
whereas the second leads to an inflammatory process with
subsequent central sensitization [38, 39]. When injected in
the orofacial area, formalin activates the trigeminal nocicep-
tive fibers [40].
The antinociceptive effect of LEO-CD observed in the
first phase may be related to the inhibition of the SP release.
Our data corroborate with the results of Leite et al. [20],
which tested the antinociceptive effect of LEO in formalin test
when injected in the paw. According to Su et al. [41], geraniol
and citronellol act in the suppression of NO production by
the modulation of iNOS enzyme and reduced expression of
cyclooxygenase 2 (COX-2), suggesting these possible actions
to LEO-CD in the second phase, which corroborate with
the anti-inflammatory activity already described for the LEO
[20].
Capsaicin acts on sensory fibers responsible for pain
transmission and activates the transient receptor potential
vanilloid subtype 1 (TRPV1) [42], an ion channel sensitive
to heat, pH acid [43], lipid mediators [44, 45], and several
natural products [46–48]. So, the decreased friction of the
orofacial region in mice following administration of LEO-
CD in the capsaicin-induced orofacial nociception test may
be related to the TRPV1 agonist effect already described for
citronellol [49], geraniol [34, 49], geranial, and neral [34].
Previous studies using ketamine, an antagonist of NMDA
receptor, on the temporomandibular joint (TMJ), showed
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Figure 3: Effect of leaf essential oil ofC. winterianus Jowitt ex Bor complexed in 𝛽-cyclodextrin (LEO-CD) on the formalin-induced orofacial
nociception. Vehicle (control), LEO-CD (50, 100, and 200mg/kg), or morphine (MOR 5mg/kg) was administered orally 60min before the
formalin injection. (a) First phase (0–5min) and (b) second phase (15–30min). Values expressed as mean ± S.E.M. (𝑛 = 6 per group).
∗𝑝 < 0.05, ∗∗𝑝 < 0.01, or ∗∗∗𝑝 < 0.001 when compared with control (ANOVA, one-way, followed by Tukey test).
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Figure 4: Effect of leaf essential oil of C. winterianus Jowitt ex Bor complexed in 𝛽-cyclodextrin (LEO-CD) on the capsaicin-induced (a)
or glutamate-induced (b) orofacial nociception. Vehicle (control), LEO-CD (50, 100, and 200mg/kg), or morphine (MOR 5mg/kg) was
administered orally 60min before the injection of capsaicin or glutamate. Values expressed as mean ± S.E.M. (𝑛 = 6 per group). ∗∗𝑝 < 0.01
or ∗∗∗𝑝 < 0.001 when compared with control (ANOVA, one-way, followed by Tukey test).
a significant decrease in glutamate-induced pain. As this neu-
rotransmitter is able to activate primary afferent nociceptors
after its release from inflamed tissues [50], the LEO-CD may
be acting as an inhibitor of the glutamatergic system, since the
frictional behavior was reducedwhen glutamate was injected,
corroborating the results described by Silva et al. [22].
Studies have suggested that the CNS depression and the
nonspecific muscle relaxation effects can reduce the response
of motor coordination and might invalidate the behavioral
tests [40, 51]. However, previous studies with LEO did not
show any interference on the motor coordination of the
animals in the rota-rod test [33], corroborating with our
results with LEO complexed in CDs. Therefore, the action
of LEO-CD on orofacial nociception tests, observed in this
study, is not entirely due to impairment as CNS depression or
muscle relaxation.
In order to investigate which brain areas are activated
after LEO-CD administration, we performed, in an unprece-
dented manner for this active compound, the immunofluo-
rescence protocol for Fos protein [52]. This protein can be
used as a target due to its release after activation of neurons,
which allows its use as a marker of neuronal activity [53].The
study of the Fos expression is indicated when the research
aims to investigate the possible mechanisms involved in the
perception and response to pain originating from the CNS
[30, 54]. After the evaluation of the Fos expression evoked by
LEO-CD administration, we observed the activation of the
trigeminal nucleus, trigeminothalamic tract, locus coeruleus,
and dorsal raphe nucleus.
The orofacial nociception test induced by formalin, which
preceded the removal of the tissue for subsequent submission
to immunofluorescence for Fos protein, occurred due to
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Figure 5: Immunofluorescence for Fos protein in neurons of brain of mice. Dorsal raphe nucleus (a, b, c, and d), locus coeruleus (e, f, g,
and h), trigeminothalamic tract (i, j, k, and l), and trigeminal nucleus (m, n, o, p) ninety minutes after treatment and 30 minutes after algesic
induction with formalin. 20𝜇m.
the application of a painful stimulus in the jaw area.This area
is innervated by the trigeminal nerve, which connects with
the trigeminal nucleus (TN) [40]. In this nucleus, there was
the expression of the Fos protein in the intermediate dose, but
there was no such an expression in the higher dose. Infor-
mation among different CNS areas is generally transmitted
by tracts, like the trigeminothalamic tract (TTT). The TTT
is also known as trigeminal lemniscuses, sending afferents
from TN to the thalamus, mediated by the glutamatergic
system [55, 56], and also sending projections to the primary
sensory cortex in order to follow the inhibitory pathway of
pain, resulting in analgesia [57, 58]. The expression of Fos
protein in these areas suggests that LEO-CD has been acting
through these pathways.
Studies with medicinal plants have showed the effect of
these plants in their intermediate dose, but not in their higher
dose, as occurred in our study. This effect has been described
formedicinal plants as hormesis effect. Our suggestion is that
the saturation of receptors by bioactive compounds present in
the high dose of LEO-CD can be inducing the mechanism of
downregulation [59].
The locus coeruleus (LC) is involved in the processing and
inhibition of pain and has been used in many classic studies
of acute pain modulation [60]. A recent study showed the
importance of glutamate in the descending inhibition in rats
[61]. According to Nygren and Olson [58], LC would receive
information from somatosensorial cortex and inhibit the pain
by descendent pathway.Therefore, data obtained with the test
of nociception induced by glutamate and previous study by
our research groupwith the LEO [21] suggest the involvement
of the glutamatergic system in the LEO-CD-action.
A previous study using an antagonist of the serotonin
(5-HT) receptor demonstrated the reduction of nociceptive
sensitivity after the formalin-induced orofacial nociception
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Figure 6: Number of positive cells for Fos in the dorsal raphe nucleus (a), locus coeruleus (b), trigeminothalamic tract (c), and spinal
trigeminal nucleus (d). Vehicle (distilled water, p.o.) or LEO-CD (50, 100, and 200mg/kg, p.o.) was administered ninety minutes before
the perfusion. Values expressed as mean ± S.E.M. (𝑛 = 6 per group). ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001 when compared with control
(ANOVA one-way followed by Tukey test).
tests, on the inflammatory phase.This suggests the serotoner-
gic pathway as one of the likely routes of nociceptive stimuli
involved in this nociceptive protocol [62].This study suggests
that LEO-CD would activate also the serotoninergic pathway
by expression of Fos protein in the dorsal raphe (DR) nucleus
[63], which activate the pain descending pathway [64].
Through the immunofluorescence data, it was possible to
show that the LEO-CD was able to activate the trigeminal
nucleus, trigeminal thalamic tract, and locus coeruleus in the
CNS, possibly by the glutamatergic pathway, confirming the
data observed in the test of glutamate-induced nociception.
Silva et al. [22] demonstrated previously the activity of the
LEO on the glutamatergic system. Our study also demon-
strated the action of LEO-CD in the dorsal raphe nucleus,
which has great influence of the serotonergic routes [63].
This suggests the action of the LEO-CD in the descending
pain pathway, particularly in specific areas responsible for the
transmission of impulses related to orofacial pain, such as
trigeminal pathway.
In summary, the use of LEO complexed in CD reduces
considerably the dose of LEO contained in the complex
when compared to the doses commonly used for the pure
LEO described in the literature. Additionally, we observed
the analgesic activity of LEO-CD on orofacial nociception
and activation of CNS areas, specifically regions, directly or
indirectly, involved in the descendent pain pathway, different
from most drugs available in the market for the treatment
of the pain nowadays. Thus, it can be concluded that the
LEO-CD can be a biotechnological option to be implanted,
in the future, for pain management, including orofacial pain,
confirming the importance of the natural products in the
world health as a potential source of new drug substances.
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